Our Pricing

Buy Mounjaro Injections Online - UK Prescription & Delivery

When you buy Mounjaro injections online UK through Cured Pharmacy, you receive genuine tirzepatide pens from £135.00 dispensed by our UK-registered pharmacy team following a free clinical consultation with a UK prescriber. Our transparent pricing and discreet next-day delivery make accessing this licensed weight loss treatment straightforward and confidential.

How Mounjaro Works for Weight Loss

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [1]. Unlike single-pathway treatments such as semaglutide, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, producing enhanced effects on appetite regulation, glucose control, and energy expenditure.

In the SURMOUNT-1 clinical trial, participants receiving the 15mg maintenance dose achieved an average body weight reduction of 22.5% over 72 weeks, compared to 2.4% with placebo [1]. This dual-agonist mechanism also improved markers of cardiovascular health, including blood pressure and lipid profiles, making Mounjaro a comprehensive metabolic intervention rather than solely an appetite suppressant [2].

The medication works by slowing gastric emptying, increasing feelings of fullness after meals, and reducing hunger signals between meals. Patients typically notice reduced appetite within the first week of treatment, though optimal weight loss results develop gradually over several months as the dose is titrated upward under prescriber guidance.

Mounjaro Dosing Schedule and Treatment Timeline

Treatment begins with a 2.5mg once-weekly injection for the first four weeks, allowing your body to adjust to the medication whilst minimising gastrointestinal side effects [3]. Your UK prescriber will then increase the dose gradually every four weeks, moving through 5mg, 7.5mg, 10mg, 12.5mg, and potentially up to the maximum 15mg maintenance dose, depending on your individual response and tolerability.

Each Mounjaro KwikPen contains four pre-filled doses at a single strength, making self-administration straightforward. The pen is injected subcutaneously into the abdomen, thigh, or upper arm once weekly on the same day each week. Most patients reach their maintenance dose within 20-24 weeks, after which weight loss typically continues for several more months before plateauing.

Clinical trials demonstrated that continuing treatment beyond the initial titration phase produces superior long-term outcomes compared to stopping early [1]. Your prescriber will review your progress regularly through follow-up consultations to optimise dosing and assess whether ongoing treatment remains clinically appropriate.

What to Expect During Your First Month

During the initial 2.5mg dose phase, most patients experience mild nausea that typically resolves within days as the body adapts. Eating smaller meals, avoiding high-fat foods, and staying well-hydrated can minimise these effects. Weight loss during the first month is usually modest—around 1-3% of body weight—as the primary goal at this stage is tolerability rather than maximum efficacy. Significant weight reduction becomes more apparent once you reach higher maintenance doses after 12-16 weeks of treatment.

Mounjaro vs Wegovy: Comparing UK Weight Loss Injections

Both Mounjaro and Wegovy are once-weekly injectable medications licensed by the MHRA for chronic weight management, but they differ in mechanism and clinical outcomes. Wegovy contains semaglutide, a single GLP-1 receptor agonist, whilst Mounjaro's tirzepatide activates both GIP and GLP-1 receptors [1][4].

Head-to-head trials have not been published, but indirect comparisons of pivotal studies suggest tirzepatide produces greater average weight loss. The SURMOUNT-1 trial showed 22.5% reduction at the highest tirzepatide dose, compared to 14.9% reduction with 2.4mg semaglutide in the STEP 1 trial [1][4]. However, individual response varies considerably, and some patients may achieve excellent results with either medication.

Wegovy may be preferred for patients who have previously responded well to GLP-1 treatments or those seeking a lower starting price point. Mounjaro is often considered for patients requiring more intensive metabolic intervention or those who have not achieved adequate results with single-agonist therapies. Your UK prescriber will assess your medical history, previous treatment responses, and individual risk factors to recommend the most suitable option.

Side Effect Profiles Compared

Both medications share similar gastrointestinal side effects—nausea, diarrhoea, constipation, and reduced appetite—which are generally mild to moderate and diminish over time [1][4]. Mounjaro's dual-agonist action may produce slightly higher rates of nausea during dose escalation, though this has not been confirmed in direct comparative trials. Serious adverse events are rare with both treatments, but neither should be used in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Eligibility Criteria and Prescription Requirements

To buy Mounjaro injections online UK through Cured Pharmacy, you must complete a clinical consultation with one of our UK-registered prescribers. Mounjaro is licensed for adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [5].

Your prescriber will review your medical history, current medications, and any contraindications before approving treatment. Mounjaro is not suitable during pregnancy or breastfeeding, and caution is required in patients with severe gastrointestinal disease, history of pancreatitis, or diabetic retinopathy. If you are taking other diabetes medications, dose adjustments may be necessary to prevent hypoglycaemia.

The online consultation takes under three minutes to complete and is reviewed by a UK prescriber, typically within hours. If approved, your prescription is sent electronically to our dispensing team, and your medication is dispatched for next-day delivery in discreet, unbranded packaging. All consultations and prescriptions are managed in accordance with GMC and GPhC guidelines, ensuring the same clinical standards as a face-to-face GP appointment.

How to Store and Administer Mounjaro Safely

Unopened Mounjaro pens must be stored in a refrigerator between 2°C and 8°C, away from the freezer compartment. Do not freeze the pens, and discard any that have been frozen. Once in use, a pen can be kept at room temperature (up to 30°C) for up to 21 days, making it convenient for travel or daily routines [3].

To administer, attach a new needle to the pen, select your prescribed dose using the dose selector, and inject into clean skin on your abdomen, thigh, or upper arm. Rotate injection sites each week to reduce the risk of lipodystrophy. The injection is subcutaneous—into the fatty tissue just beneath the skin—not into muscle. After injecting, hold the pen in place for at least five seconds to ensure the full dose is delivered.

Dispose of used needles immediately in a sharps container, which can be obtained free from most UK pharmacies or your local council. Never share pens or needles with others, even if the needle is changed, as this poses a risk of infection. If you miss a dose and it has been fewer than four days since your scheduled injection day, take the missed dose as soon as possible. If more than four days have passed, skip the missed dose and resume your regular schedule.

Managing Injection Site Reactions

Mild redness, swelling, or itching at the injection site is common and usually resolves within a few days. Applying a cool compress and rotating injection sites can minimise discomfort. If you develop persistent lumps, significant bruising, or signs of infection such as increasing warmth or pus, contact your prescriber or pharmacist for advice. Severe allergic reactions are rare but require immediate medical attention if you experience difficulty breathing, facial swelling, or widespread rash.

Long-Term Weight Maintenance and Lifestyle Support

Clinical trials demonstrate that Mounjaro is most effective when combined with a reduced-calorie diet and increased physical activity [1]. Whilst the medication significantly reduces appetite and promotes weight loss, sustainable results require behavioural changes that continue after treatment ends. NICE guidance recommends structured lifestyle programmes alongside pharmacotherapy for optimal long-term outcomes [6].

Many patients continue Mounjaro for 12-24 months to achieve and consolidate their weight loss goals. Discontinuation should be gradual and supervised by your prescriber, as stopping abruptly may lead to weight regain. Studies show that patients who maintain dietary and exercise habits established during treatment are more likely to sustain weight loss after stopping medication [6].

Our clinical team at Cured Pharmacy, led by superintendent pharmacist Tarun Kumar (GPhC 2233073), provides ongoing support through follow-up consultations to monitor progress, adjust dosing, and address any concerns. We encourage patients to track their weight, physical activity, and any side effects throughout treatment, as this information helps your prescriber optimise your care plan and determine the appropriate duration of therapy.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-1 Investigators. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. https://doi.org/10.1016/j.molmet.2020.101102
3. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). Retrieved from https://www.medicines.org.uk/emc/product/14881
4. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
5. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro (tirzepatide): authorised for chronic weight management. GOV.UK. Retrieved from https://www.gov.uk/drug-safety-update/mounjaro-tirzepatide
6. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (NICE guideline CG189). Retrieved from https://www.nice.org.uk/guidance/cg189

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment and lifestyle modifications.